

Special Issue

Atopic Dermatitis in the Precision Medicine Era: Immunological Mechanisms, Biomarkers, and Therapeutic Innovations

Message from the Guest Editor

Atopic dermatitis (AD) is one of the most prevalent chronic inflammatory skin diseases. Despite significant therapeutic advances in recent years, including biologics and small-molecule inhibitors, significant heterogeneity persists in disease manifestations, treatment responses, and long-term outcomes. The molecular understanding of AD continues to evolve rapidly, supported by progress in immunology, multi-omics profiling, neuroimmune research, and microbiome science. These breakthroughs are enabling the development of precision medicine strategies, the identification of new biomarkers, the stratification of clinical phenotypes, and the unveiling of novel therapeutic targets.

This Special Issue aims to gather high-quality contributions focused on the latest progress in AD research, spanning fundamental mechanisms, translational science, and clinical innovation. Submissions exploring immunopathology, skin barrier biology, neuroimmune signaling, microbiome interactions, therapeutic targets, biomarkers, and personalized treatment approaches are particularly encouraged. Studies on pediatric vs. adult AD, disease endotypes, and predictors of therapeutic response are also welcome.

Guest Editor

Prof. Dr. Mihail Virgil Boldeanu

Department of Immunology-Laboratory of Immunology, Universitatea de Medicina si Farmacie din Craiova, Craiova, Romania

Deadline for manuscript submissions

28 February 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/264130

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).